This topic contains a solution. Click here to go to the answer

Author Question: If you fail to reject H0 in a one-factor within-subjects analysis of variance, then you conclude ... (Read 107 times)

yoooooman

  • Hero Member
  • *****
  • Posts: 557
If you fail to reject H0 in a one-factor within-subjects analysis of variance, then you conclude that the .
 
  a. variances of each treatment condition are equal
  b. variances of each treatment condition are not equal
  c. treatment means differ only because of sampling error
  d. treatment means differ by more than sampling error alone

Question 2

If you reject H0 in a one-factor within-subjects analysis of variance, then you conclude that the .
 
  a. variances of each treatment condition are equal
  b. variances of each treatment condition are not equal
  c. treatment means differ only because of sampling error
  d. treatment means differ by more than chance alone



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

peilian

  • Sr. Member
  • ****
  • Posts: 316
Answer to Question 1

C

Answer to Question 2

D




yoooooman

  • Member
  • Posts: 557
Reply 2 on: Aug 2, 2018
:D TYSM


FergA

  • Member
  • Posts: 352
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Approximately 70% of expectant mothers report experiencing some symptoms of morning sickness during the first trimester of pregnancy.

Did you know?

Illicit drug use costs the United States approximately $181 billion every year.

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Opium has influenced much of the world's most popular literature. The following authors were all opium users, of varying degrees: Lewis Carroll, Charles, Dickens, Arthur Conan Doyle, and Oscar Wilde.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library